MIRM MIRUM PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MIRUM PHARMACEUTICALS INC reported revenue of $176M (up 37.9% from a year earlier), net income of −$67.2M and diluted EPS of −$1.06; over the last four quarters revenue was $618M and net income −$860M; for the fiscal year ended December 2025 revenue was $521M, up 54.7% on the year before.
MIRM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $521M, gross profit n/a, operating income −$22.1M, net income −$23.4M (margin -4.5%), EPS −$0.47
- Fiscal year ended Dec 2024: revenue $337M, gross profit n/a, operating income −$87.6M, net income −$87.9M (margin -26.1%), EPS −$1.85
- Fiscal year ended Dec 2023: revenue $186M, gross profit n/a, operating income −$109M, net income −$163M (margin -87.7%), EPS −$4.00
- Fiscal year ended Dec 2022: revenue $77.1M, gross profit n/a, operating income −$131M, net income −$136M (margin -176.0%), EPS −$4.02
- Fiscal year ended Dec 2021: revenue $19.1M, gross profit n/a, operating income −$173M, net income −$84.0M (margin -438.9%), EPS −$2.77
MIRM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $176M (up 37.9% year over year), net income −$67.2M, EPS −$1.06
- Quarter ended Mar 31, 2026: revenue $160M (up 43.3% year over year), net income −$790M, EPS −$13.43
- Quarter ended Dec 31, 2025 (from the annual report): revenue $149M (up 49.8% year over year), net income −$5.73M, EPS −$0.10
- Quarter ended Sep 30, 2025: revenue $133M (up 47.2% year over year), net income $2.91M, EPS $0.05
- Quarter ended Jun 30, 2025: revenue $128M (up 64.1% year over year), net income −$5.86M, EPS −$0.12
- Quarter ended Mar 31, 2025: revenue $112M (up 61.2% year over year), net income −$14.7M, EPS −$0.30
- Quarter ended Dec 31, 2024 (from the annual report): revenue $99.4M (up 42.9% year over year), net income −$23.8M, EPS −$0.49
- Quarter ended Sep 30, 2024: revenue $90.4M (up 89.4% year over year), net income −$14.2M, EPS −$0.30
- Quarter ended Jun 30, 2024: revenue $77.9M (up 107.7% year over year), net income −$24.6M, EPS −$0.52
- Quarter ended Mar 31, 2024: revenue $69.2M (up 119.1% year over year), net income −$25.3M, EPS −$0.54
- Quarter ended Dec 31, 2023 (from the annual report): revenue $69.6M (up 149.2% year over year), net income −$35.7M, EPS −$0.69
- Quarter ended Sep 30, 2023: revenue $47.7M (up 154.1% year over year), net income −$23.6M, EPS −$0.57
- Quarter ended Jun 30, 2023: revenue $37.5M (up 114.5% year over year), net income −$74.0M, EPS −$1.94
- Quarter ended Mar 31, 2023: revenue $31.6M (up 145.1% year over year), net income −$30.1M, EPS −$0.80
- Quarter ended Dec 31, 2022 (from the annual report): revenue $27.9M (up 789.3% year over year), net income −$36.4M, EPS −$0.99
- Quarter ended Sep 30, 2022: revenue $18.8M (up 275.6% year over year), net income −$35.7M, EPS −$1.02
- Quarter ended Jun 30, 2022: revenue $17.5M (up 58.9% year over year), net income −$26.9M, EPS −$0.84
- Quarter ended Mar 31, 2022: revenue $12.9M, net income −$36.6M, EPS −$1.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue $3.14M, net income $57.5M, EPS $1.91
- Quarter ended Sep 30, 2021: revenue $5.00M, net income −$47.1M, EPS −$1.55
MIRM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $55.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $10.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$70.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$120M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$133M, share buybacks n/a
MIRM balance sheet
- Jun 30, 2026: cash $331M, total assets $1.04B, total liabilities $1.06B, shareholders' equity −$10.4M
- Mar 31, 2026: cash $325M, total assets $891M, total liabilities $648M, shareholders' equity $242M
- Dec 31, 2025: cash $297M, total assets $843M, total liabilities $528M, shareholders' equity $315M
- Sep 30, 2025: cash $282M, total assets $785M, total liabilities $493M, shareholders' equity $292M
- Jun 30, 2025: cash $228M, total assets $726M, total liabilities $471M, shareholders' equity $255M
- Mar 31, 2025: cash $212M, total assets $690M, total liabilities $457M, shareholders' equity $233M
- Dec 31, 2024: cash $223M, total assets $671M, total liabilities $445M, shareholders' equity $226M
- Sep 30, 2024: cash $223M, total assets $668M, total liabilities $436M, shareholders' equity $232M
What is MIRM's revenue?
MIRUM PHARMACEUTICALS INC reported $618M of revenue over its last four quarters, through June 30, 2026.
Is MIRM profitable?
No. MIRUM PHARMACEUTICALS INC lost $860M over the last four quarters.
What is MIRM's EPS?
Diluted earnings per share over the last four quarters were −$14.54; −$1.06 in the latest quarter.